Stock News

3 Biotechs That Could Make Big Acquisitions This Year
BioNTech to buy T-cell receptor facility and platform from Gilead Sciences
BioNTech to Acquire Kite’s Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, MD
Four-Year Biktarvy Data Show High Efficacy, Durable Viral Suppression In Untreated HIV Patients
Gilead's Lenacapavir Shows High Rates Of Virologic Suppression In Heavily Treated HIV Patients
Four-Year Biktarvy® Data Presented at IAS 2021 Demonstrate High Efficacy and Durable Viral Suppression in Treatment-Naïve Adults

As seen on...